Effects of Add-on Ramelteon on Cognitive Impairment in Patients with Schizophrenia: An Open-label Pilot Trial

被引：9

作者：

Shirayama, Yukihiko ^{[1
]}

Takahashi, Michio ^{[1
]}

Suzuki, Masatoshi ^{[1
]}

Tsuruoka, Yoshiaki ^{[1
]}

Sato, Koichi ^{[1
]}

机构：

[1] Teikyo Univ, Chiba Med Ctr, Dept Psychiat, Ichihara, Chiba 2990111, Japan

来源：

CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE | 2014年 / 12卷 / 03期

关键词：

Ramelteon; Schizophrenia; Verbal learning; PLACEBO-CONTROLLED TRIAL; ADJUNCTIVE RAMELTEON; MELATONIN; DISORDER; ANTIPSYCHOTICS; MICE;

D O I：

10.9758/cpn.2014.12.3.215

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

Objective: This open label study examined the effects of ramelteon on cognitive functions in 10 outpatients with schizophrenia, Methods: Ramelteon (8 mg/day) was administered to 10 patients with schizophrenia for six months, The verbal fluency test, Trail Making Test, the Wisconsin Card Sorting Test, the Stroop Test, the Digit Span Distraction Test, Iowa Gambling Task, the Rey Auditory Verbal Learning Test were evaluated at baseline and 6 months after treatment with ramelteon, Results: Ramelteon improved significantly the scores of Rey Auditory Verbal Learning Test. Additionally, ramelteon exerted improvements in the verbal fluency and Iowa Gambling Task in 4 patients. Conclusion: Ramelteon could be a potential therapeutic drug, in adjunctive treatment of learning and memory deficits seen in patients with schizophrenia.

引用

页码：215 / 217

页数：3

共 20 条

[1]

Amman N, 2010, SCHIZOPHR RES, V121, P32

[2] Memory facilitating effects of agomelatine in the novel object recognition memory paradigm in the rat [J].

Bertaina-Anglade, Valerie ;

Drieu-La-Rochelle, Christophe ;

Mocaer, Elisabeth ;

Seguin, Laure .

PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2011, 98 (04) :511-517

[3] Placebo-Controlled Pilot Study of Ramelteon for Adiposity and Lipids in Patients With Schizophrenia [J].

Borba, Christina P. C. ;

Fan, Xiaoduo ;

Copeland, Paul M. ;

Paiva, Alexander ;

Freudenreich, Oliver ;

Henderson, David C. .

JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2011, 31 (05) :653-658

[4]

Elvevåg B, 2000, CRIT REV NEUROBIOL, V14, P1

[5] NOCTURNAL PLASMA MELATONIN LEVELS IN SCHIZOPHRENIC-PATIENTS [J].

FANGET, F ;

CLAUSTRAT, B ;

DALERY, J ;

BRUN, J ;

TERRA, JL ;

MARIECARDINE, M ;

GUYOTAT, J .

BIOLOGICAL PSYCHIATRY, 1989, 25 (04) :499-501

[6]

Grace Anthony A., 2010, Clinical Psychopharmacology and Neuroscience, V8, P1

[7] Stimulating the development of drug treatments to improve cognition in schizophrenia [J].

Green, Michael F. .

ANNUAL REVIEW OF CLINICAL PSYCHOLOGY, 2007, 3 :159-180

[8] Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antipsychotic drug perospirone:: Role of serotonin 5-HT1A receptors [J].

Hagiwara, Hiroko ;

Fujita, Yuko ;

Ishima, Tamaki ;

Kunitachi, Shinsui ;

Shirayama, Yukihiko ;

Iyo, Masaomi ;

Hashimoto, Kenji .

EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2008, 18 (06) :448-454

[9] Pharmacological approaches to the management of cognitive dysfunction in schizophrenia [J].

Harvey, Philip D. ;

McClure, Margaret M. .

DRUGS, 2006, 66 (11) :1465-1473

[10] Preventive Effects of Ramelteon on Delirium A Randomized Placebo-Controlled Trial [J].

Hatta, Kotaro ;

Kishi, Yasuhiro ;

Wada, Ken ;

Takeuchi, Takashi ;

Odawara, Toshinari ;

Usui, Chie ;

Nakamura, Hiroyuki .

JAMA PSYCHIATRY, 2014, 71 (04) :397-403

← 1 2 →